Valuation: Larimar Therapeutics, Inc.

Market Cap 377M 330M 304M 281M 534M 35.94B 543M 3.64B 1.43B 17.68B 1.41B 1.38B 61.18B P/E 2026 *
-2.56x
P/E 2027 * -3.32x
Enterprise Value 200M 175M 162M 149M 284M 19.12B 289M 1.94B 758M 9.41B 752M 736M 32.54B EV / Sales 2026 *
-
EV / Sales 2027 * 2.96x
Free-Float
96.8%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day+14.40%
1 week+28.66%
Current month+35.41%
1 month+33.23%
3 months-18.86%
6 months+22.92%
Current year+8.40%
1 week 3.21
Extreme 3.21
4.28
1 month 2.92
Extreme 2.92
4.28
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer 65 2023-07-16
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
05-18Free

Director

55,150 0.0644%
05-18
Deerfield Management Co. LP
FreeCompany 55,150 0.0644%
05-18Free

Director

55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
+14.40%+28.66%+24.40%+30.08% 377M
-0.38%+0.40%+71.69%+128.83% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.48%+10.52%+23.01%+495.47% 25.26B
-0.59%-1.00%-16.73%-12.99% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+7.22%+41.55%-24.93% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.76%+5.82%+31.23%+195.70% 14.1B
Average +1.98%+4.28%+53.17%+138.94% 23.98B
Weighted average by Cap. +1.08%+2.17%+58.71%+144.99%

Financials

2026 *2027 *
Net sales - 57.06M 49.92M 46.03M 42.55M 80.85M 5.44B 82.21M 551M 216M 2.68B 214M 210M 9.27B
Net income -157M -138M -127M -117M -223M -15.02B -227M -1.52B -596M -7.39B -591M -578M -25.56B -157M -137M -126M -117M -222M -14.94B -226M -1.51B -593M -7.35B -588M -575M -25.43B
Net Debt -176M -154M -142M -132M -250M -16.82B -254M -1.7B -667M -8.28B -662M -648M -28.64B -208M -182M -168M -155M -295M -19.83B -300M -2.01B -786M -9.76B -780M -764M -33.76B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-07-09 US$4.130 +14.40% 3,814,345
26-07-08 US$3.610 +5.87% 2,063,889
26-07-07 US$3.410 +3.65% 1,741,701
26-07-06 US$3.290 +0.92% 1,750,854
26-07-02 US$3.260 +1.56% 2,443,968
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.130USD
Average target price
14.40USD
Spread / Average Target
+248.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock